A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

Clinical trial NCT04521231 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04521231
Sponsor: Amgen
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

B Cell Precursor Acute Lymphoblastic Leukemia

Start date: 2021-01-04
Primary completion: 2027-11-24
Enrollment: 181

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.